Neurology Today

Chronic subdural hematoma requiring surgical treatment is associated with double the risk of death after 10 years compared to the general population: https://hubs.la/Q04mbFMg0

Experiencing a prolonged vegetative state does not necessarily equate to irreversible brain injury in patients with anti-NMDAR encephalitis: https://hubs.la/Q04mbP1F0

Interstitial lung disease could be a late complication in some patients with multiple sclerosis treated long-term with ocrelizumab: https://hubs.la/Q04mbVFl0

A novel therapy for Alzheimer's disease is the first to target the epigenetic dysregulation that drives progressive neurodegeneration: https://hubs.la/Q04lTR_p0

A new drug for agitation associated with dementia due to Alzheimer's disease is only the second agent—and the first non-antipsychotic—to carry an indication for the tough-to-treat symptom: https://hubs.la/Q04lVhPs0

Children with concussion may be at increased risk for more severe post-traumatic headache if they have a family history of migraine: https://hubs.la/Q04lSX640

Some patients with commercial insurance wait an average of nearly 50 days for a new neurology appointment. Here's why: https://hubs.la/Q04lSKvV0

Our June 18 issue is now live! Check out our stories on a newly approved drug for Alzheimer's agitation, wait times for new neurology appointments, post-traumatic headache in children, and much more: https://hubs.la/Q04lRsqS0

Pyridostigmine has been the de facto standard of care for treating myasthenia gravis for more than 80 years. Now, researchers have evidence confirming its measurable benefit: https://hubs.la/Q04jYcq50

Some patients with myelin oligodendrocyte glycoprotein antibody-associated disease can safely taper and discontinue maintenance immunosuppressive therapy: https://hubs.la/Q04jZ7rJ0